Identification of activators of erk5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents

Journal of Immunology

Volumn 193, Issue 7, 2014, Pages 3803-3815

  Le, Nhat Tu ^a   Takei, Yuichiro ^a   Izawa Ishizawa, Yuki ^a   Heo, Kyung Sun ^a   Lee, Hakjoo ^a   Smrcka, Alan V ^a   Miller, Benjamin L ^a   Ko, Kyung Ae ^a   Ture, Sara ^a   Morrell, Craig ^a   Fujiwara, Keigi ^a   Akaike, Masashi ^b   Abe, Jun Ichi ^a,c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CD45 ANTIGEN; CHLOROQUINE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; KRUPPEL LIKE FACTOR 2; KRUPPEL LIKE FACTOR 4; MEPACRINE; MERCAPTOPURINE; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; MONOCYTE CHEMOTACTIC PROTEIN 1; PITAVASTATIN; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; KLF2 PROTEIN, HUMAN; KLF2 PROTEIN, MOUSE; KRUPPEL LIKE FACTOR; QUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CELL INFILTRATION; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE EXPRESSION; HEART TRANSPLANTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LEUKOCYTE ROLLING; MALE; MOUSE; NONHUMAN; TRANSCRIPTION INITIATION; ALLOGRAFT; ANIMAL; CATTLE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; GRAFT REJECTION; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

ALLOGRAFTS; ANIMALS; ANTIMALARIALS; CATTLE; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKOCYTE ROLLING; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 7; QUINOLINES; TRANSCRIPTION, GENETIC; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84907202543     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400571     Document Type: Article

References (48)

1. Akaike, M., W. Che, N. L. Marmarosh, S. Ohta, M. Osawa, B. Ding, B. C. Berk, C. Yan, and J. Abe. 2004. The hinge-helix 1 region of peroxisome proliferatoractivated receptor gamma1 (PPARgamma1) mediates interaction with extracellular signal-regulated kinase 5 and PPARgamma1 transcriptional activation: involvement in flow-induced PPARgamma activation in endothelial cells. Mol. Cell. Bi ol. 24: 8691-8704.
2. Woo, C. H., T. Shishido, C. McClain, J. H. Lim, J. D. Li, J. Yang, C. Yan, and J. Abe. 2008. Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ. Res. 102: 538-545.
3. Parmar, K. M., H. B. Larman, G. Dai, Y. Zhang, E. T. Wang, S. N. Moorthy, J. R. Kratz, Z. Lin, M. K. Jain, M. A. Gimbrone, Jr., and G. García-Carden? a. 2006. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J. Clin. Invest. 116: 49-58.
4. Hayashi M.,S. W. Kim,K. Imanaka-Yoshida,T. Yoshida,E. D. Abel,B. Eliceiri,Y. Yang,R. J. Ulevitch,J. D, Lee., 2004. Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrit y and leads to endothelial failure. J. Clin. Invest., 113, 1138-1148.
5. Gimbrone, M. A., Jr., J. N. Topper, T. Nagel, K. R. Anderson, and G. Garcia-Carden?a. 2000. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann. N. Y. Acad. Sci. 902: 230 -239, discussion 239-240.
6. Davies, P. F. 2009. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat. Clin. Pract. Cardiovasc. Med. 6: 16-26.
7. Yamawaki, H., S. Lehoux, and B. C. Berk. 2003. Chronic physiological shear stress inhibits tumor necrosis factor-induced proinflammatory responses in rabbit aorta perfused ex vivo. Circulation 108: 1619-1625.
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 1998. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial choleste rol levels. N. Engl. J. Med. 339: 1349-1357.
9. Sawada, N., and J. K. Liao. 2014. Rho/Rho-Associated Coiled-Coil Forming Kinase Pathway as Therapeutic Targets for Statins in Atherosclerosis. Antioxid. Redox Signal. 20: 1251-1267.
10. Kureishi, Y., Z. Luo, I. Shiojima, A. Bialik, D. Fulton, D. J. Lefer, W. C. Sessa, and K. Walsh. 2000. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6: 1004-1010.
11. Wu, K., S. Tian, H. Zhou, and Y. Wu. 2013. Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation. Biochem. Pharmacol. 85: 1753-1760.
12. Sen-Banerjee, S., S. Mir, Z. Lin, A. Hamik, G. B. Atkins, H. Das, P. Banerjee, A. Kumar, and M. K. Jain. 2005. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 112: 720-726.
13. Wenke, K., B. Meiser, J. Thiery, D. Nagel, W. von Scheidt, K. Krobot, G. Steinbeck, D. Seidel, and B. Reichart. 2003. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 107: 93-97.
14. Parmar, K. M., V. Nambudiri, G. Dai, H. B. Larman, M. A. Gimbrone, Jr., and G. García-Carden?a. 2005. Statins exert endothelial atheroprotective effects via the KLF2 transcripti on factor. J. Biol. Chem. 280: 26714-26719.
15. Ohnesorge, N., D. Viemann, N. Schmidt, T. Czymai, D. Spiering, M. Schmolke, S. Ludwig, J. Roth, M. Goebeler, and M. Schmidt. 2010. E rk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4). J. Biol. Chem. 285: 26199-26210.
16. Lee, S. J., E. Silverman, and J. M. Bargman. 2011. The ro le of antimalarial agents in the treatment of SLE and lupus nephritis. Nat. Rev. Nephrol. 7: 718-729.
17. Alarcó n, G. S., G. McGwin, A. M. Bertoli, B. J. Fessler, J. Calvo-Alén, H. M. Bastian, L. M. Vilá, and J. D. Reveille, LUMINA Study Group. 2007. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66: 1168-11 72.
18. Lö ffler, B. M., E. Bohn, B. Hesse, and H. Kunze. 1985. Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcel lular fractions of rat liver. Biochim. Biophys. Acta 835: 448-455.
19. Bugge, E., T. M. Gamst, A. C. Hegstad, T. Andreasen, and K. Ytrehus. 1997. Mepacrine protects the isolated rat heart during h ypoxia and reoxygenation-but not by inhibition of phospholipase A2. Basic Res. Cardiol. 92: 17-24.
20. Gorbachev, A. V., A. V. Gasparian, K. V. Gurova, A. V. Gudkov, and R. L. Fairchild. 2007. Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation. Eur. J. Immunol. 37: 2257-2267.
21. Hö lscher, C. 1995. Quinacrine acts like an acetylcholine receptor antagon ist rather than like a phospholipase A2 inhibitor in a passive avoidance task in the chick. Neurobiol. Learn. Mem. 63: 206-208.
22. Le, N. T., K. S. Heo, Y. Takei, H. Lee, C. H. Woo, E. Chang, C. McClain, C. Hurley, X. Wang, F. Li, et al. 2013. A crucial role for p90RSK-mediated reduction of ERK5 transcriptional acti vity in endothelial dysfunction and atherosclerosis. Circulation 127: 486-499.
23. Overbergh, L., D. Valckx, M. Waer, and C. Mathieu. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11: 305-312.
24. Kagari, T., H. Doi, and T. Shimozato. 2002. The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 169: 1459-1466.
25. Nigro, P., K. Satoh, M. R. O'Dell, N. N. Soe, Z. Cui, A. Mohan, J. Abe, J. D. Alexis, J. D. Sparks, and B . C. Berk. 2011. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J. Exp. Med. 208: 53-66.
26. Kosuge, H., J. Suzuki, R. Gotoh, N. Koga, H. Ito, M. Isobe, M. Inobe, and T. Uede. 2003. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 75: 1374-1379.
27. Shimizu, K., P. Libby, R. Shubiki, M. Sakuma, Y. Wang, K. Asano, R. N. Mitchell, and D. I. Simon. 2008. Leukocyte integrin Mac-1 promotes acute cardiac allograft rejection. Circulation 117: 1997-2008.
28. Pires, N. M., T. W. Pols, M. R. de Vries, C. M. van Tiel, P. I. Bonta, M. Vos, E. K. Arkenbout, H. Pannekoek, J. W. Jukema, P. H. Quax, and C. J. de Vries. 2007. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation 115: 493-500.
29. French, J. K., N. P. Hurst, M. L. O'Donnell, and W. H. Betts. 1987. Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy. Ann. Rheum. Dis. 46: 42-45.
30. Lee, C. H., A. Ch awla, N. Urbiztondo, D. Liao,W. A. Boisvert, and R. M. Evans. 2003. Transcriptional repression of atherogenic inflammation: modulation by PPAR{delta}. Science 302: 453-457.
31. Takata, Y., J. Liu, F. Yin, A. R. Collins, C. J. Lyon, C. H. Lee, A. R. Atkins, M. Downes, G. D. Barish, R. M. Evans, et al. 2008. PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atheroscler osis. Proc. Natl. Acad. Sci. USA 105: 4277-4282.
32. Plutzky, J. 2011. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ. Res. 108: 1002-1016.
33. Barish, G. D., R. T. Yu, M. S. Karunasiri, D. Becerra, J. Kim, T. W. Tseng, L. J. Tai, M. Leblanc, C. Diehl, L. Cerchietti, et al. 2012. The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atheroscl erosis. Cell Metab. 15: 554-562.
34. Booth, G., T. J. Stalker, A. M. Lefer, and R. Scalia. 2002. Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes 51: 1556-1564.
35. Taylor, P. D., A. D. Wickenden, D. J. Mirrlees, and L. Poston. 1994. Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocininduced diabetes: effect of treatment with the aldose reductase inhibitor, ponalrestat. Br. J. Pharmacol. 111: 42-48.
36. Kosuge, H., G. Haraguchi, N. Koga, Y. Maejima, J. Suzuki, and M. Isobe. 2006. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation 113: 2613-2622.
37. Suzuki, J., N. Koga, H. Kosuge, M. Ogawa, G. Haraguchi, Y. Maejima, H. Saiki, and M. Isobe. 2007. Pitavastatin suppresses acute and chronic rejection in murine cardiac allografts. Transplantation 83: 1093-1097.
38. Hollenberg, S. M., L. W. Klein, J. E. Parrillo, M. Scherer, D. Burns, P. Tamburro, M. Oberoi, M. R. Johnson, and M. R. Costanzo. 2001. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 104: 3091-3096.
39. Khatri, P., S. Roedder, N. Kimura, K. De Vusser, A. A. Morgan, Y. Gong, M. P. Fischbein, R. C. Robbins, M. Naesens, A. J. Butte, and M. M. Sarwal. 2013. A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J. Exp. Med. 210: 2205-2221.
40. Ananieva, O., A. Macdonald, X. Wang, C. E. McCoy, J. McIlrath, C. Tournier, and J. S. Arthur. 2008. ERK5 regulation in naïve T-cell activation and survival. Eur. J. Immunol. 38: 2534-2547.
41. Fessler, B. J., G. S. Alarcón, G. McGwin, Jr., J. Roseman, H. M. Bastian, A. W. Friedman, B. A. Baethge, L. Vilá, and J. D. Reveille, LUMINA Study Group. 2005. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52: 1473-1480.
42. Woo, C. H., M. P. Massett, T. Shishido, S. Itoh, B. Ding, C. McClain, W. Che, S. R. Vulapalli, C. Yan, and J. Abe. 2006. ERK5 activation inh ibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPARdelta) stimulation. J. Biol. Chem. 281: 32164-32174.
43. Kasler, H. G., J. Victoria, O. Duramad, and A. Winoto. 2000. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol. Cell. Biol. 20: 8382-8389.
44. Yamakawa, T., S. Tanaka, J. Kamei, K. Kadonosono, and K. Ok uda. 2003. Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2. J. Atheroscler. Thromb. 10: 37-42.
45. Morimoto, H., K. Kondoh, S. Ni shimoto, K. Terasawa, and E. Nishida. 2007. Activation of a C-terminal transcriptional activation domain of ERK5 by autophosphorylation. J. Biol. Chem. 282: 35449-35456.
46. Yan, C., M. Takahashi, M. Okuda, J. D. Lee, and B. C. Berk. 1999. Fluid shear stress stimulates big mitogen-activated protein kinase 1 (BMK1) activity in endothelial cells. Dependence on tyrosine kinases and intracellular calcium. J. Biol. Chem. 274: 143-150.
47. Le N.T.,J.P. Corsetti,J. L. Dehoff-Sparks,C. E. Sparks,K. Fujiwara,J. Abe., 2012. Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation. Int. J. Inflamm., 2012: 678190.
48. Chao, T. H., M. Hayashi, R. I. Tapping, Y. Kato, and J. D. Lee. 1999. MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway. J. B iol. Chem. 274: 36035-36038.